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perioperative bleeding risk remains a major concern. Although the TRACER study did not meet the primary quintuple
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1049Coronary artery bypass graft (CABG) surgery is the revas-
cularization procedure of choice to treat patients with acute
coronary syndromes (ACS) in whom coronary anatomy is
not suitable for percutaneous coronary intervention. In
CABG patients, subsequent ischemic events may originate in
either grafts or in the native coronary artery. AsymptomaticSee page 1058
CI = conﬁdence interval
CV = cardiovascular
HR = hazard ratio
IQR = interquartile range
MI = myocardial infarction
NSTE = non–ST-segment
elevation
PAR = protease-activated
receptor
TIMI = Thrombolysis In
Myocardial Infarctiongraft occlusion occurs in up to 40% of patients within 1 year
(symptomatic occlusion occurs in 3.4% of patients) and is
associated with a mortality rate of up to 9% (1–3). Graft
thrombosis is thought to be the leading mechanism of graft
closure, and platelet activation may play a key role in both
early and late graft occlusion (4–8). Aspirin improves early
vein graft patency and ischemic outcomes, although signiﬁ-
cant aspirin resistance has been reported after CABG surgery,
whereas its effect on long-term patency remains uncertain
(9–12). Additional platelet inhibition through the P2Y12
receptor with clopidogrel in patients undergoing CABG after
ACS was associated with reduced ischemic rates, but
concerns regarding operative bleeding risk require pre-
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1050that inhibits thrombin-mediated platelet activation (21). In
addition, in animal models, vorapaxar analogues did not
increase surgical bleeding (22). In the TRACER (Thrombin
Receptor Antagonist for Clinical Event Reduction in Acute
Coronary Syndrome) trial, among patients with NSTE ACS,
vorapaxar did not signiﬁcantly reduce a quintuple endpoint of
cardiovascular (CV) death, myocardial infarction (MI), stroke,
recurrent ischemia with rehospitalization, or urgent coronary
revascularization, but it was associated with a reduction in the
composite of CV death, MI, and stroke, largely due to
a reduction of MI (23). Similarly, in a study of patients with
chronic atherosclerotic disease, the rates of death, MI, and
stroke were signiﬁcantly reduced by vorapaxar (24). In both
trials, vorapaxar was associated with a signiﬁcant increase in
major bleeding. We undertook a pre-speciﬁed analysis to
assess the efﬁcacy and safety of vorapaxar in TRACER
patients undergoing CABG.
Methods
The analysis population includes patients who were ran-
domized in the TRACER trial (n ¼ 12,944), for which the
primary results and study design have been published
(23,25). Brieﬂy, patients were enrolled if they presented with
acute symptoms of coronary ischemia within 24 h before
hospital presentation and with at least 1 of the following:
cardiac troponin (I or T) or creatine kinase-myocardial
band levels higher than the upper limit of normal, new
ST-segment depression >0.1 mV, or transient ST-segment
elevation (<30 min) of >0.1 mV in 2 contiguous leads.
Patients were randomly assigned in a 1:1 ratio to receive
vorapaxar (40-mg loading dose and 2.5-mg daily mainte-
nance dose thereafter) or matching placebo with stratiﬁca-
tion according to intention to use a glycoprotein IIb/IIIa
inhibitor (vs. none) and intention to use a parenteral direct
thrombin inhibitor (vs. other antithrombins).
This analysis included patients who underwent CABG
during index hospitalization after they were randomized and
began the study drug. Because time to CABG may vary
across centers, and because it may be local practice to dis-
charge patients and then schedule CABG, we performed an
additional analysis to include all CABG surgeries performed
within 30 days of randomization.
The study protocol recommended that the study drug be
continued during CABG. Temporary interruptions were
deﬁned as any disruption in study drug 2 days, but then
resumed. Permanent discontinuation was deﬁnitive prema-
ture interruption of study treatment. For the efﬁcacy
endpoints, the accrual period was from CABG to the date of
site notiﬁcation of study termination. The endpoints for this
analysis were: 1) the composite of CV death, MI, stroke,
recurrent ischemia with rehospitalization, or urgent coronary
revascularization (primary); and 2) the composite of CV
death, MI, or stroke (secondary) from the TRACER study.
For bleeding endpoints, the accrual period was from
CABG to the last dose of randomized treatment. TheCABG-related major bleeding was deﬁned according to the
Thrombolysis In Myocardial Infarction (TIMI) criteria and
was pre-speciﬁed as part of the TRACER trial event deﬁ-
nition. To provide further detail, CABG-related major
bleeding was deﬁned as any hemorrhage meeting any of the
following criteria: 1) fatal bleeding (i.e., bleeding that di-
rectly results in death); 2) perioperative intracranial bleeding;
3) reoperation after closure of the sternotomy incision to
control bleeding; 4) transfusion of 5 U of whole blood or
packed red blood cells within 48 h; or 5) chest tube output
>2 l within 24 h. All efﬁcacy and bleeding events in the
TRACER study were systematically adjudicated by a central
clinical events committee. All bleeding events were classiﬁed
according to the TIMI and GUSTO (Global Use of Stra-
tegies to Open Occluded Coronary Arteries) scales.
Associations between treatment assignments and out-
comes were assessed using time-to-event analysis. Hazard
ratios (HRs) and 95% conﬁdence intervals (CIs) were cal-
culated using Cox proportional hazards regression modeling,
with the adjustment of randomization stratiﬁcation factors
and baseline covariates. Event rates were estimated by the
Kaplan-Meier method. To test interaction, because patients
had to be classiﬁed as either “CABG” or “no CABG” within
a common time point (discharge from the index event), the
event accrual period was from discharge to site notiﬁcation. A
sensitivity analysis was also carried out by including all events
since randomization and accounting for propensity of having
CABG.
The SAS version 9.3 (SAS Institute, Cary, North Caro-
lina) was used to perform statistical analyses. The p values
were not adjusted for multiple comparisons. The TRACER
study was approved by an institutional review committee,
and all patients gave informed consent.Results
Baseline characteristics. In total, 1,312 (10.1%) of 12,944
patients enrolled in the TRACER trial underwent CABG
surgery during the index hospitalization (vorapaxar n ¼ 639;
placebo n ¼ 673). There were 1,510 patients who under-
went CABG within 30 days of randomization (vorapaxar
n ¼ 750; placebo n ¼ 760). The overall study population
was followed for a median of 502 days (interquartile range
[IQR]: 349 to 667 days). The 2 treatments arms were well
balanced regarding baseline characteristics for patients
undergoing CABG (Table 1).
Study treatment and concomitant antiplatelet agents.
The median time to CABG in patients treated with vor-
apaxar was 120 h (IQR: 47 to 194 h) and with placebo was
119 h (IQR: 48 to 214 h) (Table 2). At randomization, there
was a lower utilization of thienopyridine in patients later
undergoing CABG (72% CABG vs. 89% no CABG),
although use was similar between the vorapaxar and placebo
groups. Before CABG, the study drug was interrupted in
23% of placebo patients and in 26% of vorapaxar patients.
Among those who had the treatment withheld before
Table 1
Baseline Characteristics of Patients With and Without CABG During
Index Hospitalization by Treatment Arm
Characteristic
CABG No CABG
Placebo
(n ¼ 673)
Vorapaxar
(n ¼ 639)
Placebo
(n ¼ 5,798)
Vorapaxar
(n ¼ 5,834)
Age (yrs) 64 (58–71) 64 (58–71) 64 (57–72) 64 (58–71)
75 89 (13.2) 95 (14.9) 1,007 (17.4) 1,015 (17.4)
Female 155 (23.0) 132 (20.7) 1,667 (28.8) 1,678 (28.8)
Race or ethnic group*
White 568 (84.7) 548 (85.8) 4,940 (85.4) 4,981 (85.6)
Black 16 (2.4) 17 (2.7) 145 (2.5) 134 (2.3)
Asian 37 (5.5) 32 (4.9) 496 (8.6) 491 (8.4)
Other 48 (7.2) 42 (6.6) 201 (3.5) 211 (3.6)
Body mass index (kg/m2) 28.1 (25.4–31.4) 28.2 (25.2–31.7) 27.7 (25.0–31.1) 27.7 (25.0–31.1)
Region of enrollment
North America 242 (36.0) 243 (38.0) 1,452 (25.0) 1,467 (25.2)
Latin America 83 (12.3) 59 (9.2) 337 (5.8) 369 (6.3)
Western Europe 253 (37.6) 231 (36.2) 2,677 (46.2) 2,678 (45.9)
Eastern Europe 50 (7.4) 58 (9.1) 692 (11.9) 687 (11.8)
Asia 25 (3.7) 21 (3.3) 449 (7.7) 441 (7.6)
Australia or New Zealand 20 (3.0) 27 (4.2) 191 (3.3) 192 (3.3)
Cardiovascular risk factors
Hypertension 482 (71.6) 482 (75.4) 4,109 (70.9) 4,055 (69.5)
Hyperlipidemia 418 (62.1) 417 (65.3) 3,606 (62.2) 3,621 (62.1)
Diabetes mellitus 237 (35.2) 220 (34.4) 1,793 (30.9) 1,820 (31.2)
Current tobacco use 176 (26.2) 182 (28.5) 1,611 (27.8) 1,567 (26.9)
Creatinine clearance
<30 ml/min 7 (1.1) 9 (1.5) 81 (1.5) 93 (1.7)
30–60 ml/min 62 (9.7) 59 (9.7) 681 (12.4) 675 (12.2)
Cardiovascular disease history
MI 143 (21.3) 170 (26.6) 1,747 (30.1) 1,731 (29.7)
PCI 99 (14.7) 127 (19.9) 1,432 (24.7) 1,432 (24.6)
CABG 20 (3.0) 23 (3.6) 746 (12.9) 754 (12.9)
Stroke 28 (4.2) 21 (3.3) 234 (4.0) 270 (4.6)
PAD 46 (6.8) 52 (8.2) 422 (7.3) 416 (7.1)
Positive for troponin or
CK-MB
627 (93.6) 602 (94.2) 5,410 (93.9) 5,411 (93.5)
ECG ﬁndings
ST-segment depression 257 (38.2) 252 (39.4) 1,865 (32.2) 1,825 (31.3)
ST-segment elevationy 36 (5.4) 29 (4.5) 342 (5.9) 329 (5.4)
Killip classz
II 32 (4.8) 34 (5.4) 228 (4.0) 200 (3.5)
III or IV 6 (0.90) 6 (0.94) 55 (0.96) 63 (1.1)
Use of oral antiplatelets at
baseline
Thienopyridine 488 (72.1) 452 (70.7) 5,151 (88.8) 5,216 (89.4)
Aspirin
100 mg 373 (58.7) 340 (55.7) 3,405 (60.4) 3,405 (60.5)
>100 mg 263 (41.4) 271 (44.4) 2,231 (39.6) 2,227 (39.5)
Values are median (interquartile range) or n (%). *Race or ethnic group was reported by investigators after interviews with patients. yPatients with
transient (<30 min) ST-segment elevation were eligible. zAccording to the Killip classiﬁcation, class II indicates cardiac S3 or rales on 50% of the
lung ﬁelds, class III indicates rales on >50% of the lung ﬁelds, and class IV indicates signs of cardiogenic shock.
CABG ¼ coronary artery bypass grafting; CK-MB ¼ creatine kinase-myocardial band; ECG ¼ electrocardiogram; MI ¼ myocardial infarction; PAD ¼
peripheral artery disease; PCI ¼ percutaneous coronary intervention.
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1051surgery, the median time from last dose to CABG was 6
days (IQR: 4 to 8 days) for placebo and vorapaxar patients.
In those who underwent CABG, 39% in the placebo
group and 38% in the vorapaxar group received clopidogrel
within 5 days of CABG. Clopidogrel at discharge was usedin 16% of placebo patients and in 19% of vorapaxar patients,
which was much lower than among non-CABG patients
(84.3% placebo; 84.9% vorapaxar).
Efﬁcacy of vorapaxar in CABG patients. In patients
undergoing CABG during index hospitalization (n¼ 1,312),
Table 2 Peri-CABG Antiplatelet Therapies
Placebo
(n ¼ 673)
Vorapaxar
(n ¼ 639)
Study drug loading dose to CABG (h) 119 (48–214) 120 (47–194)
Study drug interrupted 155 (23) 166 (26)
Time from last study drug dose after
interruption (days)
6 (4–8) 6 (4–8)
Clopidogrel received 5 days from CABG 263 (39) 242 (38)
Clopidogrel at discharge 108 (16) 121 (19)
Values are median (interquartile range) or n (%).
CABG ¼ coronary artery bypass grafting.
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1052the primary endpoint occurred in 43 patients in the vora-
paxar group and in 70 patients in the placebo group (2-year
Kaplan-Meier rates: 8.2% and 12.9%, respectively), corre-
sponding to a 45% reduction (adjusted HR: 0.55; 95% CI:
0.36 to 0.83; p ¼ 0.005) (Table 3). The reduction in events
post-discharge was higher among patients who underwent
CABG during index hospitalization (HR: 0.46; 95% CI:
0.28 to 0.77; p ¼ 0.003) compared with those who did not
undergo CABGduring index hospitalization (HR: 0.97; 95%
CI: 0.87 to 1.08; p ¼ 0.59). There was a statistically signif-
icant interaction between CABG and vorapaxar (p ¼ 0.012)
(Fig. 1). All components of the primary endpoint were
numerically lower with vorapaxar. When all patients who
underwent CABG in the ﬁrst 30 days after randomization
were included, the effect on post-CABG events remained
consistent, with a 48% reduction with vorapaxar (HR: 0.52;
95% CI: 0.36 to 0.76; p ¼ 0.001), and the interaction
between CABG and vorapaxar treatment effect on post-
discharge events remained signiﬁcant with groups deﬁned
at 30 days (p ¼ 0.028).
Vorapaxar was also associated with lower occurrence of the
key secondary endpoint (43 events; 2-year Kaplan-Meier rateTable 3
Primary and Key Secondary Efﬁcacy End
Underwent CABG During Index Hospitali
Placebo
(2-yr Kaplan-Meier Rate)
CABG during index hospitalization n ¼ 673
Primary endpoint 70 (12.9%)
CV death 26
MI 26
Stroke 17
Urgent revascularization 10
Recurrent ischemia with
hospitalization
6
Key secondary endpointy 58 (10.2%)
CABG within 30 days n ¼ 760
Primary endpointz 83 (13.5%)
Key secondary endpointy 70 (8.6%)
Values are n (%) or %. Interaction of index CABG and vorapaxar: primary end
Interaction of CABG within 30 days and vorapaxar: primary endpoint adjusted
events is from CABG to site notiﬁcation. Kaplan-Meier rates reported are 2-y
patients undergoing CABG during index hospitalization were adjusted for ra
group is placebo arm, adjusted for baseline covariates. yCardiovascular deat
infarction, stroke, urgent revascularization, and recurrent ischemia with reho
CABG ¼ coronary artery bypass grafting; CI ¼ conﬁdence interval; CV ¼ cof 8.2%) compared with placebo (58 events; 2-year Kaplan-
Meier rate of 10.2%) in patients undergoing CABG
(adjusted HR: 0.66; 95% CI: 0.43 to 1.01; p ¼ 0.057). The
reduction in post-discharge events was numerically higher
among patients who underwent CABG (HR: 0.54; 95% CI:
0.31 to 0.94; p ¼ 0.030) compared with those who did
not undergo CABG (HR: 0.89; 95% CI: 0.78 to 1.01;
p ¼ 0.065). The interaction between randomized treatment
and CABG was not statistically signiﬁcant (p ¼ 0.209)
(Fig. 2). Results were comparable when all patients who
underwent CABG in the ﬁrst 30 days post-randomization
were included (HR: 0.60; 95% CI: 0.40 to 0.88; p ¼ 0.010).
CABG-related bleeding. The CABG-related TIMI major
bleeding was not a statistically signiﬁcant difference between
vorapaxar and placebo, although it was numerically higher
with vorapaxar (HR: 1.36; 95% CI: 0.92 to 2.02; p ¼ 0.12),
as it was for GUSTO severe bleeding related to CABG
(HR: 1.35; 95% CI: 0.80 to 2.29; p ¼ 0.26) (Table 4). The
number of patients who required repeated surgery to control
bleeding was similar between groups (vorapaxar n ¼ 30
[4.7%]; placebo n ¼ 31 [4.6%]). Fatal bleeding occurred in 2
placebo patients and in none of the vorapaxar patients.
Among those who continued the study drug up to the time
of surgery, TIMI major CABG-related bleeding occurred in
43 (8.0%) placebo patients and in 54 (11.0%) vorapaxar
patients.
Among those who discontinued the randomized drug
throughout CABG, TIMI major CABG-related bleeding
occurred in 9 (7.3%) placebo patients and in 13 (9.3%) vor-
apaxar patients. Reoperation for bleeding in this subgroupwas
similar between the vorapaxar (n ¼ 7 [5.0%]) and placebo
(n ¼ 7 [5.6%]) groups, and in the group of patients who
continued the drug through the perioperative period (vor-
apaxar: n ¼ 23 [4.6%]; placebo: n ¼ 24 [4.4%]). In patientspoints Post-CABG Among Patients Who
zation and Within 30 Days of Randomization
Vorapaxar
(2-yr Kaplan-Meier Rate) HR* (95% CI) p Value
n ¼ 639 d d
43 (8.2%) 0.55 (0.36–0.83) 0.005
14 d d
21 d d
14 d d
5 d d
2 d d
43 (8.2%) 0.66 (0.43–1.01) 0.057
n ¼ 750 d d
49 (8.1%) 0.52 (0.36–0.76) 0.001
48 (6.7%) 0.60 (0.40–0.88) 0.010
point adjusted p ¼ 0.012; key secondary endpoint adjusted p ¼ 0.21.
p ¼ 0.028; key secondary endpoint adjusted p ¼ 0.24. The number of
ear estimates. HRs for comparisons between vorapaxar and placebo in
ndomization stratiﬁcation factors and baseline covariates. *Reference
h, myocardial infarction, and stroke. zCardiovascular death, myocardial
spitalization.
ardiovascular; HR ¼ hazard ratio; MI ¼ myocardial infarction.
Figure 1 Primary Efﬁcacy Endpoint by Index CABG and Treatment Post-Discharge From Index Hospitalization
CABG ¼ coronary artery bypass grafting.
JACC Vol. 63, No. 11, 2014 Whellan et al.
March 25, 2014:1048–57 Vorapaxar in ACS Patients Undergoing CABG
1053who received clopidogrel within 5 days of surgery (vorapaxar
n ¼ 242; placebo n ¼ 263), TIMI major CABG-related
bleeding occurred in 28 (11.6%) patients with vorapaxar and
in 23 (8.7%) patients with placebo, and reoperation for
bleeding occurred in 10 (4.1%) patients with vorapaxar and 13
(4.9%) patients with placebo. Among patients who received
their last dose of clopidogrel 5 days before CABG
(vorapaxar n ¼ 214; placebo n ¼ 231), TIMI major CABG-
related bleeding occurred in 26 (12.1%) patients with vor-
apaxar and in 17 (7.4%) patients with placebo, and reoperation
for bleeding occurred in 11 (5.1%) patients with vorapaxar and
in 12 (5.2%) patients with placebo.
There was a mild excess in chest tube drainage in patients
treated with vorapaxar versus placebo at 8 h (350 ml vs.
308 ml), at 24 h (635 ml vs. 580 ml), and total (830 ml vs.
780 ml).
When all CABG surgeries performed during the ﬁrst 30
days from randomization were included, the results for
CABG-related major bleeding were similar (Table 4).
Bleeding after discharge. In patients who underwent
CABG during index hospitalization, bleeding after dis-
charge increased with vorapaxar (Table 5). In the CABG
population, GUSTO moderate or severe bleeding at 2 years
was 4.0% with vorapaxar and 2.2% with placebo (HR: 1.60;
95% CI: 0.75 to 3.42). The TIMI major bleeding was
infrequent in the CABG cohort, but increased with vor-
apaxar (2-year Kaplan-Meier rates of 1.4% with vorapaxar
and 0.8% with placebo; HR: 1.83; 95% CI: 0.54 to 6.26). In
the CABG cohort, there was 1 patient (0.2%) with intra-
cranial hemorrhage who received vorapaxar and no intra-
cranial hemorrhage with placebo. In the non-CABG
population, the GUSTO moderate or severe bleeding rate at
2 years was 4.1% with vorapaxar and 2.8% with placebo(HR: 1.38; 95% CI: 1.09 to 1.75). There was no statistically
signiﬁcant interaction (p ¼ 0.75).
Discussion
In the TRACER study patients who underwent CABG, we
observed that adding vorapaxar versus placebo to standard-
of-care practices reduced the occurrence of the primary
endpoint with an estimated relative hazard reduction of
45%. The improvement in the primary endpoint post-
discharge for patients randomized to vorapaxar and under-
going CABG during index hospitalization appeared to be
much stronger than that observed in the non-CABG cohort,
a ﬁnding supported by a statistically signiﬁcant interaction.
In the CABG cohort, vorapaxar was also associated with
a 34% reduction of CV death, MI, or stroke (a larger esti-
mated effect than in the main TRACER study cohort),
although the interaction was not statistically signiﬁcant.
There was a nonsigniﬁcant numerical increase in surgical
bleeding with vorapaxar without increased occurrence of
reoperations for bleeding. There was also an increase in non-
CABG bleeding, which is consistent with the main results
of the TRACER trial.
These results suggest that PAR-1 antagonism may be
a viable therapeutic option to reduce recurrent ischemic
events post-CABG. All components of the primary end-
point, including mortality, were numerically lower with
vorapaxar after CABG, and the efﬁcacy of vorapaxar
seemed overall enhanced post-CABG. It is possible that
PAR-1 activation is an important mechanism leading to
graft failure. Particularly, increased thrombin generation
after CABG may induce a higher susceptibility to the
action of PAR-1 antagonists (26,27). Concomitant
Figure 2 Key Secondary Endpoint by Index CABG and Treatment Post-Discharge From Index Hospitalization
CABG ¼ coronary artery bypass grafting.
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1054antiplatelet therapy might have also played a role. In fact,
consistent with registry data, use of clopidogrel at discharge
was much lower in CABG patients than in non-CABG
patients (18% vs. 85%, respectively). It is possible that
the effect of vorapaxar is stronger when added to aspirin
only versus when added to aspirin and clopidogrel as tripleTable 4
CABG-Related Bleeding Among Patients
Index Hospitalization or Within 30 Days
Endpoint Placebo
CABG during index hospitalization n ¼ 671
TIMI major 49 (7.3)
GUSTO severe 26 (3.9)
GUSTO moderate/severe 101 (15.1)
Fatal bleeding 2 (0.3)
Reoperation for bleeding 31 (4.6)
Chest tube drainage, ml
8 h 308 (200–510)
24 h 580 (389–865)
Total 780 (490–1,260)
CABG within 30 days n ¼ 758
TIMI major 56 (7.4)
GUSTO severe 29 (3.8)
GUSTO moderate/severe 111 (14.6)
Fatal bleeding 2 (0.3)
Chest tube drainage, ml
8 h 310 (200–500)
24 h 600 (400–875)
Total 800 (500–1,270)
Values are n (%) or median (interquartile range). *Reference group is place
GUSTO ¼ Global Use of Strategies to Open Occluded Coronary Arteries;
abbreviations as in Table 3.oral antiplatelet therapy. It is interesting that vorapaxar was
associated with a numerical reduction of urgent revascu-
larization (not associated with an MI) in CABG patients,
but not in non-CABG patients. Vorapaxar may affect the
mechanism leading to urgent revascularization in CABG
patients (e.g., graft failure), but not in non-CABG patientsWho Underwent CABG During
of Randomization
Vorapaxar OR* (95% CI) p Value
n ¼ 639 d d
62 (9.7) 1.36 (0.92–2.02) 0.12
33 (5.2) 1.35 (0.80–2.29) 0.26
116 (18.2) 1.25 (0.93–1.68) 0.13
0 (0.0) d d
30 (4.7) d d
350 (220–550) d d
635 (420–1,000) d d
830 (530–1,381) d d
n ¼ 750 d d
66 (8.8) 1.21 (0.83–1.75) 0.32
37 (4.9) 1.30 (0.79–2.10) 0.29
126 (16.8) 1.18 (0.89–1.55) 0.25
0 (0.0) d d
350 (220–550) d d
650 (420–995) d d
830 (530–1,370) d d
bo arm, adjusted for baseline covariates.
OR ¼ odds ratio; TIMI ¼ Thrombolysis In Myocardial Infarction; other
Table 5
Bleeding Endpoints Post-Discharge Among Patients Who Underwent CABG During
Index Hospitalization and/or Within 30 Days of Randomization
Endpoint
Placebo
(2-yr Kaplan-Meier rate)
Vorapaxar
(2-yr Kaplan-Meier rate) HR* (95% CI) p Value
CABG during index hospitalization n ¼ 671 n ¼ 639
GUSTO criteria
Moderate or severe bleeding 11 (2.2) 17 (4.0) 1.60 (0.75–3.42) 0.225
Severe bleeding 2 (0.3) 7 (1.4) 3.64 (0.76–17.53) 0.107
TIMI criteria
Clinically signiﬁcant bleeding 23 (6.0) 48 (11.2) 2.16 (1.31–3.56) 0.002
Major bleeding 4 (0.8) 7 (1.4) 1.83 (0.54–6.26) 0.334
Major or minor bleeding 6 (1.1) 15 (3.7) 2.59 (1.01–6.68) 0.049
Intracranial hemorrhage 0 (0.0) 1 (0.2) d d
CABG within 30 days n ¼ 758 n ¼ 750
GUSTO criteria
Moderate or severe bleeding 10 (2.0) 16 (3.3) 1.65 (0.74–3.64) 0.219
Severe bleeding 0 (0.0) 9 (1.6) d d
TIMI criteria
Clinically signiﬁcant bleeding 27 (6.3) 49 (9.9) 1.83 (1.14–2.93) 0.012
Major bleeding 2 (0.4) 7 (1.2) 3.75 (0.78–18.14) 0.100
Major or minor bleeding 5 (0.9) 14 (3.0) 2.83 (1.02–7.86) 0.046
Intracranial hemorrhage 0 (0.0) 2 (0.4) d d
Values are n (%). *Reference group is placebo arm, adjusted for baseline covariates.
Abbreviations as in Tables 3 and 4.
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1055(e.g., in-stent restenosis, progression of pre-existing
stenosis).
The use of antiplatelet therapy in addition to aspirin
therapy is controversial due to the increased risk of bleeding
that undermines the reduction in clinical events. In the
CURE (Clopidogrel in Unstable angina to prevent Re-
current ischemic Events) trial (14), the reduction of CV
death, MI, or stroke in the CABG cohort was consistent
with the main CURE trial results. However, available
evidence is controversial concerning a beneﬁt in adding
clopidogrel post-CABG to improve vein graft patency and
CV events (28–30). Ticagrelor, a reversibly binding, direct-
acting oral P2Y12 receptor antagonist, was associated with
a 16% reduction in CV death, MI, or stroke, which was
consistent overall with the main trial results, although tica-
grelor appeared to have amore robust effect onmortality in the
CABG cohort (15,16). The CABG bleeding rates were
increased and comparable for both ticagrelor and clopidogrel
(15,18). Based on these results, guidelines recommend
withholding either ticagrelor or clopidogrel 5 days prior to
CABG surgery (31). A third P2Y12 antagonist, prasugrel
(vs. clopidogrel), was associated with signiﬁcantly reduced
mortality after adjusting for pre-operative risk in the few
patients participating in the TRITON–TIMI 38 (Trial to
Assess Improvement in Therapeutic Outcomes by Opti-
mizing Platelet Inhibition with Prasugrel–Thrombolysis In
Myocardial Infarction 38) trial who underwent follow-up
CABG surgery (32). However, prasugrel requires an even
longer interruption (7 days) before surgery, and the improved
clinical outcomes with prasugrel need to be weighed against
the substantial increased risk of CABG-related bleeding. In
contrast, vorapaxar (or matching placebo) was to be continuedperioperatively, as recommended by the TRACER study
protocol.
In contrast with the main TRACER study results, in
which there was a signiﬁcant increase in major bleeding with
vorapaxar, the perioperative safety proﬁle of vorapaxar
seemed acceptable in this analysis. In patients who received
vorapaxar, there was a numerical increase in major CABG-
related bleeding that did not meet statistical signiﬁcance,
a modest increase in chest tube drainage, and no trend
indicating increased rates of reoperation to control bleeding.
It is important to note that most CABG procedures were
performed while vorapaxar was still active, unlike current
recommendations for P2Y12 antagonists. In fact, 75% of
patients in the vorapaxar group did not have interruption in
study treatment before CABG. In addition, because the
effect of duration of a single dose of vorapaxar is 2 to 3 weeks
and the median time to CABG was only 120 h, even when
the study drug was interrupted, it was still expected to be
within its biological activity time frame. Our results conﬁrm:
1) earlier ﬁndings that show no increase in surgical bleeding
in an animal model with a vorapaxar analogue; and 2)
preliminary results among 76 patients undergoing CABG in
the phase II study, in which vorapaxar did not increase
surgical bleeding (33). Overall, these data suggest the
possibility of using vorapaxar during the perioperative
period. The contrast between surgical and spontaneous
bleeding effects of vorapaxar observed in this analysis could
be related to different roles of PARs under different path-
ophysiologic circumstances.
It is possible that, during surgery, a high concen-
tration of thrombin can increase activity of the PAR-4
receptordwhich, in humans, requires higher concentrations
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1056of thrombin to be activated than PAR-1 doesdtherefore
creating a “rescue” mechanism (34). Alternatively, thrombin
generation during cardiopulmonary bypass surgery may
cause platelet activation that leads to the desensitization of
platelets and a reduction of platelet reactivity. By reducing
perioperative, thrombin-mediated platelet activation, vor-
apaxar may prevent desensitization of platelets. Finally, it is
possible that the PAR-1 receptor may have a more limited
role in normal hemostasis after major vessel injury (35).
Future analysis to also assess the safety of vorapaxar in the
setting of noncardiac surgery will be helpful to further deﬁne
how PAR-1 antagonism could be tolerated in the setting of
surgical procedures.
The effect of vorapaxar on bleeding events (mostly rep-
resenting spontaneous bleeding) after discharge in CABG
patients is largely consistent with the overall TRACER
study results, particularly in terms of a relative increase in
bleeding. However, it is noteworthy that the absolute risk of
bleeding is lower in CABG patients than in non-CABG
patients, possibly due to the selection of candidates who
undergo surgery and the lower concomitant use of clopi-
dogrel. Therefore, the trade-off between efﬁcacy and
bleeding may be favorable to vorapaxar use in CABG
patients, if the results of the present analysis are conﬁrmed in
a prospective randomized clinical trial.
Study limitations. Because the current analysis is not
a randomized comparison of vorapaxar and placebo, the
results have no immediate applicability in clinical practice
and should be interpreted as hypothesis-generating. This is
a pre-speciﬁed analysis of a post-randomization subgroup
within a large clinical trial. Thus, we cannot rule out that
study participation and study drug assignment may have
inﬂuenced the choice of candidates for CABG, or that
factors other than CABG itself may have inﬂuenced the
results. It is important to note, however, that this was
a double-blinded study and the time to CABG was short, so
it is unlikely that there is bias of CABG referral based on
treatment assignment. The vorapaxar and placebo groups
were well balanced in the CABG and the non-CABG
cohorts regarding baseline demographics. However,
unmeasured confounders cannot be excluded with certainty.
Because the primary focus of the TRACER trial was not
the evaluation of vorapaxar in patients undergoing CABG,
data that may have improved our understanding of the
underlying mechanism supporting these resultsdincluding
the reason for patient referral to CABG, method for har-
vesting vein grafts, use of cardiopulmonary bypass circuit, or
post-operative imaging of vein graftsdwere not collected as
part of the analysis (36,37). In particular, we did not collect
imaging to assess graft failure; therefore, we are unable to
provide a mechanistic explanation in support of the observed
effect.
The CABG group represents 10% of the overall study
population, and the study was not stratiﬁed by CABG.
Some of the results and lack of statistical signiﬁcance may
have been inﬂuenced by insufﬁcient power. No adjustmentfor multiple comparisons was performed so as not to reduce
sensitivity in generating hypotheses.
Conclusions
In a large, nonrandomized cohort of patients with NSTE
ACS who participated in the TRACER trial and subse-
quently underwent CABG, we have observed a marked
reduction in the primary endpoint among patients assigned
to vorapaxar and enhanced efﬁcacy in comparison with the
non-CABG cohort. The current analysis suggests that
vorapaxar may have an acceptable safety proﬁle for CABG-
related bleeding. After discharge, rates of major bleeding
were relatively low in CABG patients, but were increased
with vorapaxar, consistent with the main trial. These results
should be considered exploratory, yet they suggest that
PAR-1 antagonism could be a potentially attractive strategy
to reduce recurrent ischemic events in CABG patients, and
this hypothesis warrants conﬁrmatory evidence from future,
appropriately designed, randomized clinical trials.
Reprint requests and correspondence: Dr. David J. Whellan,
Division of Cardiology, Thomas Jefferson University Hospital, 1015
Chestnut Street, Suite 317, Philadelphia, Pennsylvania 19107.
E-mail: djw150@jefferson.edu.REFERENCES
1. Nathoe HM, van Dijk D, Jansen EW, et al. A comparison of on-pump
and off-pump coronary bypass surgery in low-risk patients. N Engl J
Med 2003;348:394–402.
2. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary
intervention versus coronary-artery bypass grafting for severe coronary
artery disease. N Engl J Med 2009;360:961–72.
3. Fabricius AM, Gerber W, Hanke M, Garbade J, Autschbach R,
Mohr FW. Early angiographic control of perioperative ischemia after
coronary artery bypass grafting. Eur J Cardiothorac Surg 2001;19:853–8.
4. Boyle EM Jr., Lille ST, Allaire E, Clowes AW, Verrier ED. Endo-
thelial cell injury in cardiovascular surgery: atherosclerosis. Ann Thorac
Surg 1997;63:885–94.
5. Reilly CF, McFall RC. Platelet-derived growth factor and transforming
growth factor-beta regulate plasminogen activator inhibitor-1 synthesis
in vascular smooth muscle cells. J Biol Chem 1991;266:9419–27.
6. Verrier ED, Boyle EM Jr. Endothelial cell injury in cardiovascular
surgery. Ann Thorac Surg 1996;62:915–22.
7. Nachman RL, Silverstein R. Hypercoagulable states. Ann Intern Med
1993;119:819–27.
8. Ishiwata S, Tukada T, Nakanishi S, Nishiyama S, Seki A. Post-
angioplasty restenosis: platelet activation and the coagulation-ﬁbrinolysis
system as possible factors in the pathogenesis of restenosis. Am Heart J
1997;133:387–92.
9. Goldman S, Copeland J, Moritz T, et al. Long-term graft patency
(3 years) after coronary artery surgery. Effects of aspirin: results of a VA
cooperative study. Circulation 1994;89:1138–43.
10. Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin
improves vein graft patency early and late after coronary artery bypass
graft surgery. A placebo-controlled, randomized study. Circulation
1991;83:1526–33.
11. Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical
evaluation of platelet aspirin resistance after coronary artery bypass
surgery. Circulation 2003;108:542–7.
12. Mangano DT. Multicenter Study of Perioperative Ischemia Research
Group. Aspirin and mortality from coronary bypass surgery. N Engl J
Med 2002;347:1309–17.
JACC Vol. 63, No. 11, 2014 Whellan et al.
March 25, 2014:1048–57 Vorapaxar in ACS Patients Undergoing CABG
105713. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK.
Effects of clopidogrel in addition to aspirin in patients with acute
coronary syndromes without ST-segment elevation. N Engl J Med
2001;345:494–502.
14. Fox KA, Mehta SR, Peters R, et al. Beneﬁts and risks of the combi-
nation of clopidogrel and aspirin in patients undergoing surgical
revascularization for non-ST-elevation acute coronary syndrome: the
Clopidogrel in Unstable angina to prevent Recurrent ischemic Events
(CURE) trial. Circulation 2004;110:1202–8.
15. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in
patients with acute coronary syndromes undergoing coronary artery
bypass surgery: results from the PLATO (Platelet Inhibition and
Patient Outcomes) trial. J Am Coll Cardiol 2011;57:672–84.
16. Varenhorst C, Alström U, Scirica BM, et al. Factors contributing to the
lower mortality with ticagrelor compared with clopidogrel in patients
undergoing coronary artery bypass surgery. J Am Coll Cardiol 2012;60:
1623–30.
17. Tricoci P, Roe MT, Mulgund J, et al. Clopidogrel to treat patients with
non-ST-segment elevation acute coronary syndromes after hospital
discharge. Arch Intern Med 2006;166:806–11.
18. Biancari F, Airaksinen KE, Lip GY. Beneﬁts and risks of using clo-
pidogrel before coronary artery bypass surgery: systematic review and
meta-analysis of randomized trials and observational studies. J Thorac
Cardiovasc Surg 2012;143:665–75.
19. Raivio P, Kuitunen A, Suojaranta-Ylinen R, Lassila R, Petäjä J.
Thrombin generation during reperfusion after coronary artery bypass
surgery associates with postoperative myocardial damage. J Thromb
Haemost 2006;4:1523–9.
20. Lison S, Dietrich W, Braun S, et al. Enhanced thrombin generation
after cardiopulmonary bypass surgery. Anesth Analg 2011;112:37–45.
21. Leonardi S, Tricoci P, Mahaffey KW. Promises of PAR-1 inhibition in
acute coronary syndrome. Curr Cardiol Rep 2012;14:32–9.
22. Chintala M, Vemulapalli S, Kurowski S, et al. SCH 530348, a novel
oral antiplatelet agent, demonstrated no bleeding risk alone or in
combination with aspirin and clopidogrel in cynomolgus monkeys
(abstr). Arterioscler Thromb Vasc Biol 2008;28:e138–9.
23. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist
vorapaxar in acute coronary syndromes. N Engl J Med 2012;366:
20–33.
24. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the
secondary prevention of atherothrombotic events. N Engl J Med 2012;
366:1404–13.
25. TRA*CER Executive and Steering Committees. The Thrombin
Receptor Antagonist for Clinical Event Reduction in Acute Coronary
Syndrome (TRA*CER) trial: study design and rationale. Am Heart J
2009;158:327–34.
26. Boisclair MD, Lane DA, Philippou H, Sheikh S, Hunt B. Thrombin
production, inactivation and expression during open heart surgerymeasured by assays for activation fragments including a new ELISA for
prothrombin fragment F1 þ 2. Thromb Haemost 1993;70:253–8.
27. Petäjä J, Pesonen E, Fernández JA, Vento AE, Rämö OJ, Grifﬁn JH.
Cardiopulmonary bypass and activation of antithrombotic plasma
protein C. J Thorac Cardiovasc Surg 1999;118:422–9, discussion
429–31.
28. Kulik A, Le May MR, Voisine P, et al. Aspirin plus clopidogrel versus
aspirin alone after coronary artery bypass grafting: the Clopidogrel
After Surgery for Coronary Artery Disease (CASCADE) trial.
Circulation 2010;122:2680–7.
29. de Leon N, Jackevicius CA. Use of aspirin and clopidogrel after
coronary artery bypass graft surgery. Ann Pharmacother 2012;46:
678–87.
30. Gao G, Zheng Z, Pi Y, Lu B, Lu J, Hu S. Aspirin plus clopidogrel
therapy increases early venous graft patency after coronary artery bypass
surgery: a single-center, randomized, controlled trial. J Am Coll Car-
diol 2010;56:1639–43.
31. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline
for coronary artery bypass graft surgery: a report of the American
College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines. J Am Coll Cardiol 2011;58:e123–210.
32. Smith PK, Goodnough LT, Levy JH, et al. Mortality beneﬁt with
prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting
cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol
2012;60:388–96.
33. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of
SCH 530348 in patients undergoing non-urgent percutaneous coro-
nary intervention: a randomised, double-blind, placebo-controlled
phase II study. Lancet 2009;373:919–28.
34. Judge HM, Jennings LK, Moliterno DJ, et al. PAR-1 antagonists
inhibit thrombin-induced platelet activation whilst leaving the PAR4-
mediated response intact. Paper presented at: XXIV Congress of the
International Society on Thrombosis and Haemostasis; June 29 to July
4, 2013; Amsterdam, the Netherlands. Available at: http://www.
eventure-online.com/eventure/publicAbstractView.do?id¼215172
&congressId¼6839. Accessed May 1, 2013.
35. Cornelissen I, Palmer D, David T, et al. Roles and interactions among
protease-activated receptors and P2ry12 in hemostasis and thrombosis.
Proc Natl Acad Sci U S A 2010;107:18605–10.
36. Lopes RD, Haﬂey GE, Allen KB, et al. Endoscopic versus open vein-
graft harvesting in coronary-artery bypass surgery. N Engl J Med 2009;
361:235–44.
37. Shroyer AL, Grover FL, Hattler B, et al. On-pump versus off-pump
coronary-artery bypass surgery. N Engl J Med 2009;361:1827–37.Key Words: bypass - coronary disease - myocardial infarction -
platelets - thrombin.
